{"resourceType":"ValueSet","id":"2.16.840.1.113762.1.4.1032.61","meta":{"versionId":"9","lastUpdated":"2018-05-09T01:07:38.000-04:00"},"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.61","version":"20180509","name":"Immunotherapy","status":"active","date":"2018-05-09T01:00:04-04:00","publisher":"MITRE Steward","compose":{"include":[{"system":"http://www.icd10data.com/icd10pcs","version":"2022","concept":[{"code":"XW03351","display":"Introduction of Blinatumomab Antineoplastic Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 1"},{"code":"XW033C3","display":"Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 3"},{"code":"XW04351","display":"Introduction of Blinatumomab Antineoplastic Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 1"},{"code":"XW043C3","display":"Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 3"}]}]},"expansion":{"identifier":"urn:uuid:a593fb1a-02be-415c-a4a3-35ac2432e63b","timestamp":"2022-06-10T08:40:55-04:00","total":0,"offset":0,"parameter":[{"name":"count","valueInteger":1000},{"name":"offset","valueInteger":0}]}}